Clinical trial · Interventional
CXCR4 Targeted PET Imaging in APA Preoperative Localization Diagnosis
A Single Center Study on the Evaluation of Diagnostic Efficacy of CXCR4 Targeted PET Imaging in Primary Aldosteronism
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The goal of this clinical trial is to evaluate the effectiveness of CXCR4 targeted PET imaging in preoperative localization diagnosis of primary aldosteronism (PA). Participants diagnosed with PA will be asked to be scanned by 68Ga-PentixaFor PET, and then underwent adrenal venous sampling (AVS). Then, the responsible adrenal adenoma will be resected by adrenalectomy, and examined with pathological section and staining. Researchers will compare the sensitivity and specificity between 68Ga-PentixaFor PET imaging and AVS in preoperative localization diagnosis of PA.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Aldosterone-Producing Adenoma | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| CXCR4 | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- CXCR4
- description
- scanned by 68Ga-PentixaFor PET imaging
- interventionNames
- Diagnostic Test: CXCR4
Primary outcomes (7)
- measure
- renin
- timeFrame
- immediately after admission
- description
- measure the level of renin in blood
- measure
- aldosterone
- timeFrame
- immediately after admission
- description
- measure the level of aldosterone in blood
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: * Patients with PA, confirmed by an elevated aldosterone/renin ratio (ARR) and an intravenous salt loading test. * The patient has provided written informed consent authorisation before participating in the study. * The patient is 18 to 70 years of age at the time of consent. Exclusion Criteria: * Refusal by the patients to undergo 68Ga-PentixaFor PET/CT, AVS, CT, or adrenalectomy. * Suspicion of familial hyperaldosteronism type 1 (FH-1) or type 3 (FH-3). * Suspicion of adrenocortical carcinoma. * Severe comorbidity potentially interfering with treatment or health-related quality of life. * Patients need to take drugs that interfere with clinical research. * Any medical condition present that in the opinion of the investigator will affect patients clinical status. * Pregnancy or lactation. * Estimated glomerular filtration rate \<40mL/min/1.73m2. * Interfering treatment in between 68Ga-PentixaFor PET/CT and AVS.
References
Publications (3)
- RESULTCui Y, Zhang Y, Ding J, Wang H, Ma X, Wang O, Chang X, Sun H, Huo L, Tong A. A Rare Aldosterone-Producing Adenoma Detected by 68Ga-pentixafor PET-CT: A Case Report and Literature Review. Front Endocrinol (Lausanne). 2019 Nov 29;10:810. doi: 10.3389/fendo.2019.00810. eCollection 2019. PMID 31849839
- RESULTChaman Baz AH, van de Wiel E, Groenewoud H, Arntz M, Gotthardt M, Deinum J, Langenhuijsen J. CXCR4-directed [68Ga]Ga-PentixaFor PET/CT versus adrenal vein sampling performance: a study protocol for a randomised two-step controlled diagnoStic Trial Ultimately comparing hypertenSion outcome in primary aldosteronism (CASTUS). BMJ Open. 2022 Aug 23;12(8):e060779. doi: 10.1136/bmjopen-2022-060779. PMID 35998969
- RESULTDing J, Zhang Y, Wen J, Zhang H, Wang H, Luo Y, Pan Q, Zhu W, Wang X, Yao S, Kreissl MC, Hacker M, Tong A, Huo L, Li X. Imaging CXCR4 expression in patients with suspected primary hyperaldosteronism. Eur J Nucl Med Mol Imaging. 2020 Oct;47(11):2656-2665. doi: 10.1007/s00259-020-04722-0. Epub 2020 Mar 23. PMID 32206838